<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02041871</url>
  </required_header>
  <id_info>
    <org_study_id>P120207</org_study_id>
    <nct_id>NCT02041871</nct_id>
  </id_info>
  <brief_title>Interest of PReOPerative Immunonutrition in Liver Surgery for Cancer</brief_title>
  <acronym>PROPILS</acronym>
  <official_title>Interest of Preoperative Immunonutrition in Liver Resection for Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nestlé Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the efficacy of preoperative immunonutrition in reducing postoperative morbidity
      after liver resection for cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perioperative immunonutrition has been developed to improve the immuno metabolic host
      response and outcome in postoperative period and has been proven to be beneficial in reducing
      significantly postoperative infectious complications and length of hospital stay in patients
      undergoing elective gastrointestinal surgery for tumors. To date, the effects of preoperative
      oral immunonutrition (ORAL IMPACT) in non cirrhotic patients undergoing liver resection for
      cancer are unknown. The purpose of this study is to determine whether the administration of a
      short-term preoperative oral immunonutrition can reduce postoperative morbidity in
      non-cirrhotic patients undergoing liver resection for malignant tumours.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall complications classified in grade 2-3-4 or 5 by DINDO-CLAVIEN</measure>
    <time_frame>In the first 30 postoperative days after Liver surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>30 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hepatectomy</condition>
  <condition>Elective Hepatectomy</condition>
  <condition>Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>Impact control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ORAL IMPACT Powder 74g within 250ml of water, 3 times per day during 7 days before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral immunonutrition</intervention_name>
    <description>Powder 74g within 250ml of water, 3 times per day during 7 days before surgery</description>
    <arm_group_label>Impact control</arm_group_label>
    <other_name>ORAL IMPACT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Powder 74g within 250ml of water, 3 times per day during 7 days before surgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Non cirrhotic patient

          -  Elective liver surgery for cancer (primary or secondary malignant tumours)

          -  Hepatectomy including at least 1 segment or 3 wedge resections

        Exclusion Criteria:

          -  Liver resection for benign lesions

          -  Liver resection associated with biliary tract surgery

          -  Liver resection associated with gastro-intestinal surgery

          -  Cirrhosis, defined by transient elastography (Fibroscan®) or by liver biopsy

          -  Renal failure

          -  Pregnancy or nursing women

          -  History of hypersensitivity or allergy to arginine, omega-3 fatty acids, or
             nucleotides

          -  Inability to take oral nutrition

          -  Mental condition rendering the subject unable to understand the nature, end-points and
             consequences of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis CASTAING, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oriana CIACIO, MD</last_name>
    <phone>+33 (1) 45 59 64 32</phone>
    <email>oriana.ciacio@pbr.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thibault VORON</last_name>
    <phone>+33 (1) 45 59 64 32</phone>
    <email>thibault.voron@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AP-HP, Paul Brousse Hospital, Centre Hepato-Biliaire</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oriana CIACIO, MD</last_name>
      <email>oriana.ciacio@pbr.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Oriana CIACIO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2014</study_first_submitted>
  <study_first_submitted_qc>January 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2014</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Surgery</keyword>
  <keyword>Hepatectomy</keyword>
  <keyword>Immunonutrition</keyword>
  <keyword>Cancer</keyword>
  <keyword>Morbidity</keyword>
  <keyword>Postoperative complication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

